Session » Sjögren's Syndrome - Poster I: Translational Science

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 655

Comprehensive Immuno-Phenotyping of Follicular Helper T Cells and B Cell Subpopulations in Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 667

Cytokine and Chemokine Levels in Serum and Saliva As Disease Activity Biomarkers in Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 663

Cytokine and Chemokine Levels in Serum and Tears As Disease Activity Biomarkers in Patients with Primary Sjögren´s Syndrome

9:00AM-11:00AM: Abstract Number: 658

Decreased Expression of Ten Micro-RNAs in Plasmacytoid Dendritic Cells of Patients with Primary SS Indicates Dysregulation on Multiple Levels

9:00AM-11:00AM: Abstract Number: 661

Epitope Specificity and End-Organ Susceptibility Dictates Anti-Ro52 Mediated Salivary Gland Dysfunction

9:00AM-11:00AM: Abstract Number: 656

ERdj5 Function Is Involved in Inflammatory Manifestations of Sjögren’s Syndrome in the Salivary Glands

9:00AM-11:00AM: Abstract Number: 660

Expression of the Chemokine Receptor CXCR5 Is Decreased in the Periphery of Patients with Primary Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 657

Expression of Type-III Interferons (IFNλs) and Their Receptor in Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 670

Identification and Characterization of Sjogren’s Syndrome-Associated Genetic Variants in the IL12A and DDX6-CXCR5 Loci

9:00AM-11:00AM: Abstract Number: 666

Immunoglobulin N-Glycosylation Acquired By Somatic Hypermutation As a Potential Mechanism for Non-Specific B Cell Activation in Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 659

Low Dose IL-2 Therapy Can Restore the Balance of Th17 and Treg Cells in Refractory Patients with Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 664

Regulation of Interferon Signaling By a Calcium-Induced miRNA in Primary Human Salivary Gland Epithelial Cells

9:00AM-11:00AM: Abstract Number: 669

RNA-Sequencing Reveals Sjogren’s Syndrome Anti-Ro Negative Patients Share Similar Pathways to Multiple Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 665

Salivary Gland Secretome: A Novel Tool to Identify Biomarkers of Dryness and Immunopathology in Primary Sjogren’s Syndrome and Non-Autoimmune Sicca Patients

9:00AM-11:00AM: Abstract Number: 672

Sjogren Big Data Project: Influence of Geolocation on the Phenotypic Expression at Diagnosis in 8310 Patients (North-to-South Gradient)

9:00AM-11:00AM: Abstract Number: 673

Sjögren’s Syndrome (SS): The Role of Traditional (SS-A/SS-B) and Novel Antibodies in Diagnosis

9:00AM-11:00AM: Abstract Number: 671

Steered Screening for Sjögren Syndrome in Patients with Sicca Syndrome. Role of Salival Beta-2 Microglogulin

9:00AM-11:00AM: Abstract Number: 674

Targeting Glandular IL-21-Production in Primary Sjogren′s Syndrome Patients By Immunomodulatory Treatment

9:00AM-11:00AM: Abstract Number: 654

The Level of B-Cell Active Cytokines and Soluble B-Cell Activating Factor/a Proliferation-Inducing Ligand Receptors in Patients with Primary Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 668

The TNFAIP3 F127C Coding Variation in Sjogren’s Syndrome: Results from a Greek Cohort

9:00AM-11:00AM: Abstract Number: 662

The Unusual Cross-Reactivity of Anti Muscarinic Receptor 3 Monclonal Antibodies Derived from Salivary Glands of Sjögren’s Syndrome Patients to Ro Peptides

9:00AM-11:00AM: Abstract Number: 653

Thrombospondin-1 Is Highly Expressed By Salivary Gland Epithelial Cells of Sjögren’s Syndrome Patients, Both Constitutively and upon Exposure to Necrotic Cells Debris

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].